Table 5 PSM between HHL and EHL Patients Resulting in 21 Pairs of Matched Patients

Age, median (range)

54 (36–77)

59 (37–73)

0.282

60 (39–72)

56 (337–73)

0.419

Gender (male), n (%)

32 (66.7)

16 (59.3)

0.521

10 (47.6)

12 (57.1)

0.537

HBsAg positive, n (%)

30 (62.5)

11 (40.7)

0.069

8 (38.1)

10 (47.6)

0.533

Child-Pugh Class (B), n (%)

2 (4.2)

3 (11.1)

0.344

1 (4.8)

2 (9.5)

> 0.99

AST, IU/L, median (range)

30.5 (10–449)

33 (18–451)

0.191

28 (17–154)

33 (18–451)

0.150

CA-199 (U/mL), median (range)

36.2 (0.6–5533)

80.8 (0–1000)

0.971

36.2 (0.6–5533)

123.2 (0–1000)

0.595

Tumor diameter (cm), median (range)

6.55 (3–17)

7 (2–13)

0.948

6.5 (3–17)

7 (2–13)

0.854

Unifocal lesions, n (%)

24 (50.0)

16 (59.3)

0.440

11 (52.4)

10 (47.6)

0.758

Major hepatectomy, n (%)

35 (72.9)

20 (74.1)

0.913

14 (66.7)

15 (71.4)

0.739

Negative surgical margin, n (%)

45 (93.8)

25 (92.6)

> 0.99

19 (90.5)

10 (90.5)

> 0.99

Blood loss (mL), median (range)

375 (20–1500)

300 (50–1000)

0.067

400 (20–1500)

300 (50–1000)

0.190

Transfusion, n (%)

17 (35.4)

3 (11.1)

0.022

9 (42.9)

3 (14.3)

0.040

Major complications, n (%)

3 (6.3)

1 (3.7)

> 0.99

0 (0)

1 (4.8)

> 0.99

Tumor differentiation, poor, n (%)

16 (33.3)

8 (29.6)

0.741

4 (19.0)

7 (33.3)

0.292

Macrovascular invasion, n (%)

10 (20.8)

3 (11.1)

0.453

2 (9.5)

3 (14.3)

> 0.99

Microvascular invasion, n (%)

11 (22.9)

4 (14.8)

0.400

3 (14.3)

4 (19.0)

> 0.99

Perineural invasion, n (%)

3 (6.3)

2 (7.4)

> 0.99

1 (4.8)

2 (9.5)

> 0.99

Periductal invasion, n (%)

2 (4.2)

2 (7.4)

0.616

2 (9.5)

2 (9.5)

> 0.99

Cirrhosis, n (%)

25 (52.1)

11 (40.7)

0.345

7 (33.3)

10 (47.6)

0.346

Lymph node metastasis, n (%)

18 (37.5)

18 (66.7)

0.015

8 (38.1)

13 (61.9)

0.123

Antiviral therapy, n (%)

14 (29.2)

3 (11.1)

0.073

1 (4.8)

3 (14.3)

0.606

Adjuvant therapy, n (%)

22 (45.8)

8 (29.6)

0.169

8 (38.1)

8 (38.1)

> 0.99